Filing Details
- Accession Number:
- 0001209191-14-030157
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-05-01 16:01:29
- Reporting Period:
- 2014-04-30
- Filing Date:
- 2014-05-01
- Accepted Time:
- 2014-05-01 16:01:29
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1338042 | Aegerion Pharmaceuticals Inc. | AEGR | Pharmaceutical Preparations (2834) | 202960116 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1557420 | Craig Fraser | C/O Aegerion Pharmaceuticals, Inc. 101 Main Street, Suite 1850 Cambridge MA 02142 | Pres., Us/Int. Comm. & Manuf. | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2014-04-30 | 2,250 | $13.01 | 2,250 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2014-04-30 | 1,079 | $43.18 | 1,171 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2014-04-30 | 1,171 | $43.90 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2014-04-30 | 2,250 | $0.00 | 2,250 | $13.01 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 66,500 | 2021-11-01 | No | 4 | M | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Plan"). The Plan was adopted for purposes of investment portfolio diversification.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.59 to $43.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.59 to $44.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The 100,000 shares underlying this option vest monthly over a four-year period commencing on November 1, 2011.
Billionaire Hedge Funds
